|Day Low/High||6.16 / 6.34|
|52 Wk Low/High||4.46 / 14.93|
More Immunotherapy Buyouts Likely After Kite Sale
Data Highlighting the Non-viral Sleeping Beauty Gene Delivery System to Be Presented during Oral Session
Investors in ZIOPHARM Oncology Inc saw new options begin trading this week, for the April 2018 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Company to Host Conference Call Today at 4:30 p.m. ET
Stereotactic Study Arm Serves as Runway to Clinical Studies of Controlled IL-12 Gene Therapy in Pediatric Patients and in Combination with Checkpoint Inhibitors
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
- Updated Survival Through Late May to be Presented on June 5, 2017 -
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in ZIOPHARM Oncology Inc , where a total of 8,160 contracts have traded so far, representing approximately 816,000 underlying shares. That amounts to about 62.6% of ZIOP's average daily trading volume over the past month of 1.3 million shares.
Phase 1 Study Expected to Initiate in Third Quarter 2017
Doug Kass shares his thoughts on Facebook, Allergan and Eli Lilly.
Investors in ZIOPHARM Oncology Inc saw new options become available this week, for the June 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZIOP options chain for the new June 16th contracts and identified one put and one call contract of particular interest.
Doug Kass shares his thoughts on whether Judgment Day is here for the financials and discusses General Electric, Apple and Caterpillar.
Two CAR Targets Selected Enable Range of Potential Therapeutic Candidates for Both Solid and Liquid Tumors
Company to Host Quarterly Conference Calls
Doug Kass shares his thoughts on Twitter and talks about Sears.
Investors in ZIOPHARM Oncology Inc saw new options begin trading this week, for the May 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ZIOP options chain for the new May 19th contracts and identified one put and one call contract of particular interest.
In trading on Tuesday, shares of ZIOPHARM Oncology Inc crossed below their 200 day moving average of $5.89, changing hands as low as $5.85 per share. ZIOPHARM Oncology Inc shares are currently trading off about 6.2% on the day.
Here's how to rake in the profits off some potential big breakouts.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.